We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD).
Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient.
Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.
Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient.
Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.
Location: United States, Maryland, Gaithersburg
Employees: 1-10
Total raised: $5.95M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | Pathway Bi... | pathwaybio... |
| - | Maryland M... | momentum.u... |
| - | BioHealth ... | biohealthi... |
| - | Boutique V... | boutiquevc... |
| 05.04.2024 | Tachyon Ve... | tachyon.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.05.2021 | Seed | $5.7M | - |
| 10.08.2020 | Seed | $250K | Maryland M... |
Mentions in press and media 8
| Date | Title | Description |
| 24.05.2026 | Maryland Stem Cell Research Commission: $12.6 Million Awarded To Advance Regenerative Medicine Research | The Maryland Stem Cell Research Commission announced 38 new awards totaling more than $12.6 million through the Maryland Stem Cell Research Fund (MSCRF) to support stem cell and regenerative medicine research, technology development, commer... |
| 07.09.2022 | University System of Maryland Names Mike Ravenscroft Managing Director of the Maryland Momentum Fund | Baltimore, Md. (Sept. 7, 2022) – The University System of Maryland (USM) has named Mike Ravenscroft as Managing Director of the Maryland Momentum Fund (MMF), a $16 million investment fund that supports early stage companies affiliated with ... |
| 02.07.2021 | Viewpoint: Md. startups are poised for takeoff, but the entrepreneurial ecosystem is still in its infancy | After leading the University System of Maryland Maryland Momentum Fund for nearly two years — performing due diligence on over 250 companies and making 22 investments and counting — I’m able to offer a full picture on Maryland’s strengths a... |
| 28.05.2021 | miRecule Closes $5.7M Funding Round | miRecule, Inc., a Gaithersburg MD-based biotech company focused on the development of RNA therapeutics, raised $5.7M in funding. The round was led by Alexandria Venture Investments, with participation from Boutique Venture Partners, Pathway... |
| 27.05.2021 | miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy | GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding ... |
| 27.05.2021 | miRecule Raises $5.7M Seed Financing | GAITHERSBURG, MD, miRecule announced today it has closed over $5.7 million in seed funding. >> Click here for more funding data on miRecule >> To export miRecule funding data to PDF and Excel, click here miRecule, an emer... |
| 17.08.2020 | Money Moves: These 6 DMV companies raised funding from $250K up to $31.3M | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at dc@technical.ly. Following strong funding trends from previous quarters, companies in the DMV region are still closing ma... |
| 10.08.2020 | USM Maryland Momentum Fund Invests $250,000 in $3.5M Seed Round of miRecule Inc. | Biotech company is developing breakthrough RNA therapies for cancer and muscular dystrophy |